Ligand validation:2VWD

NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose

NAG is a Ligand Of Interest in 2VWD designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
2VWD_NAG_B_1611	86%	63%	0.093	0.962	0.56	0.86	-	-	0	0	100%	0.9333
2VWD_NAG_B_1607	70%	50%	0.114	0.93	0.58	1.34	-	3	0	0	100%	0.9333
2VWD_NAG_A_1609	60%	52%	0.137	0.923	0.49	1.34	-	3	0	0	100%	0.9333
2VWD_NAG_B_1609	46%	62%	0.195	0.93	0.48	0.96	-	1	0	0	100%	0.9333
2VWD_NAG_A_1610	40%	63%	0.206	0.918	0.45	0.94	-	1	0	0	100%	0.9333
2VWD_NAG_B_1608	38%	54%	0.198	0.9	0.59	1.18	-	1	0	0	100%	0.9333
2VWD_NAG_A_1611	16%	65%	0.29	0.86	0.48	0.87	-	1	0	0	100%	0.9333
2VWD_NAG_B_1610	13%	46%	0.291	0.832	0.57	1.49	-	4	0	0	100%	0.9333
2VWD_NAG_A_1613	7%	48%	0.325	0.782	0.56	1.41	-	1	0	0	100%	0.9333
2VWD_NAG_A_1612	4%	28%	0.446	0.812	0.59	2.25	-	5	3	0	100%	0.9333
2VSM_NAG_A_1605	65%	51%	0.126	0.927	0.61	1.26	-	2	2	0	100%	0.9333
8JA5_NAG_A_701	18%	71%	0.336	0.926	0.39	0.71	-	-	0	0	100%	0.9333
3D12_NAG_A_1210	12%	20%	0.156	0.683	1.77	1.61	3	4	0	0	100%	0.9333
3D11_NAG_A_1210	0%	53%	0.215	0.224	0.46	1.32	-	3	1	1	100%	0.9333
3H0C_NAG_A_794	100%	56%	0.021	0.995	0.61	1.08	-	1	0	0	100%	0.9333
5F9W_NAG_A_510	100%	88%	0.023	0.994	0.24	0.43	-	-	0	0	100%	0.9333
5LDS_NAG_C_1002	100%	69%	0.022	0.994	0.55	0.65	-	-	0	0	100%	0.9333
5O5D_NAG_A_601	100%	65%	0.022	0.994	0.32	0.99	-	1	0	0	100%	0.9333
6MUG_NAG_G_629	100%	76%	0.022	0.994	0.35	0.58	-	-	0	0	100%	0.9333

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.